SCENARIOS-Stroke study data to be watershed for Bayer stock

Posted on October 15, 2010 at 08:24 AM EDT

FRANKFURT, Oct 15 (Reuters) - Study results due shortly on its Xarelto anti-blood-clotting drug will determine whether Bayer gets a crack at a $12 billion plus market and will mark a turning point for its stock price.

Related Stocks:

BIOREM Bay National Corporation Bristol-Myers Squibb Co. Johnson & Johnson Pfizer, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates